



ASX Announcement

A\$30 MILLION TO BE RAISED UNDER UNDERWRITTEN PLACEMENT AND SPP

- Imricor has raised A\$28.45 million via an institutional placement at A\$2.35 per CDI
- A fully underwritten security purchase plan (SPP) will be offered to eligible CDI holders in Australia and New Zealand to raise an additional A\$1.55 million

29 October 2020 – Minneapolis, United States – Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) announces that it has completed the bookbuild for an institutional placement to new and existing sophisticated and professional investors to raise A\$28.45 million at A\$2.35 per CHESS Depositary Interest (**CDI**) (each representing the same number of shares of Class A common stock) (**Placement**).

In addition, the Company will launch a fully underwritten security purchase plan for eligible CDI holders in Australia and New Zealand (**SPP**), capped at A\$1.55 million.

The new CDIs issued in the capital raising will rank equally with existing Imricor CDIs.

Placement details

The Placement will be completed in a single tranche without stockholder approval, with 12,106,383 CDIs (representing the same number of shares of Class A Common Stock) to be issued under the Company's existing placement capacity in accordance with ASX Listing Rule 7.1 (846,241 CDIs) and ASX Listing Rule 7.1A (11,260,142 CDIs).

Moelis Australia Advisory Pty Ltd (**Moelis**) acted as sole lead manager for the capital raising.

Mr. Steve Wedan, President and CEO of Imricor, stated:

"We are seeing solid progress in our commercialisation plans, particularly in light of COVID, with eight clinical sites contracted in Europe, five of which have executed purchasing agreements over the last six weeks. As anticipated, we have experienced an acceleration in lab roll outs following the conclusion of the European summer vacation season and expect this trend to continue throughout the last quarter of 2020.

"Further to the eight sites now contracted we have an additional twelve sites with the potential to sign agreements by the end of 2020. Allowing for the possibility that some of these may execute early in the new year, we expect a total of 14 clinical sites to have agreements in place by the end of 2020, assuming no unanticipated COVID related disruptions.

"Our pipeline of new sites continues to grow, supported by strong clinical outcomes, our collaborative relationships with leading MRI vendors Siemens and Philips and growing interest across the medical profession to deliver the benefits of MRI guided ablations in treating heart arrhythmias. We remain excited about the opportunities ahead as we continue to drive an acceleration in lab adoption into 2021 and establish a new and long-awaited standard of care for interventional medicine.

“We greatly appreciate the support shown by both our existing and new institutional investors, with strong demand received for the placement, which will support our future growth through geographical expansion, expanding indications for cardiac ablation procedures and for products beyond cardiac ablation.”

SPP details

The Placement will be followed by an offer to existing eligible Australian and New Zealand CDI holders to participate in a fully underwritten SPP. The SPP will provide such CDI holders with an opportunity to increase their holding by up to A\$30,000.

The issue price under the SPP will be the lower of A\$2.35 (the issue price under the Placement) and the price equal to a 2.5% discount (rounded down to the nearest cent) to the volume-weighted average price of the CDIs during the five trading days up to, and including, the closing date of the SPP.

The SPP will be capped at A\$1.55 million and is fully underwritten by Moelis. Imricor will scale-back applications on a pro-rata basis if total demand exceeds A\$1.55 million.

Existing eligible CDI holders wishing to participate in the SPP should carefully read the SPP Offer Booklet and accompanying form, which are expected to be dispatched on or around 6 November 2020. A copy of the SPP Offer Booklet will also be available on the ASX website.

“Our intention for the SPP is to give non-institutional investors an opportunity to participate in this fundraising, at the same or a lower price as under the Placement,” commented Wedan. “Our last SPP needed to be withdrawn due to market volatility as the COVID-19 pandemic was breaking, so we hope eligible investors will be excited to take this opportunity to contribute further to our efforts to shape the future of interventional medicine.”

Use of proceeds

The funds raised in the Placement and SPP will be applied as follows:

Raise size of \$30.0 million		
Use of proceeds	A\$m	% of funds
Sales and marketing ¹	6.3	20.9
Development, clinical and regulatory ²	17.7	59.2
Offer costs	1.6	4.7
Other working capital ³	4.4	15.2
Total	30.0	100.0%

1. Includes additional sales and clinical support staff to drive lab adoption and increased catheter utilisation; market research for pipeline products and expanding geographies; and increased tradeshow presence.
2. Includes pipeline product development; acceleration of certain pipeline products; expanding approvals across geographies; medical device regulation compliance; and product life cycle support.



3. Includes general working capital requirements (including inventory, other support and resources and spending to support gross margin improvements).

Following settlement of the Placement, Imricor's pro-forma 30 September 2020 cash balance will increase from approximately US\$7.8 million to approximately US\$26.8 million. The funds raised under the SPP will further increase Imricor's pro-forma 30 September 2020 cash balance by approximately US\$1.1 million, to approximately US\$27.9 million.

Key dates for capital raising*

Record date for SPP	Thursday, 29 October 2020
Placement and SPP announced to ASX	Friday, 30 October 2020
Settlement of new CDIs issued under Placement	Wednesday, 4 November 2020
Allotment and normal trading of CDIs issued under Placement	Thursday, 5 November 2020
Dispatch of SPP Offer Booklet and SPP Opening Date	Friday, 6 November 2020
SPP Closing Date	Monday, 30 November 2020
Allotment of new CDIs under SPP	Friday, 4 December 2020
SPP CDIs commence trading on ASX	Monday, 7 December 2020
Dispatch of holding statements to SPP participants	Monday, 7 December 2020

* Please note, the dates set out above are indicative only and are subject to change without notice.

Authorised for release by Steve Wedan, Executive Chair, President, and CEO.

ENDS

Further Information

Investors:

Steve Wedan
Executive Chair, President and CEO
Email: steve.wedan@imricor.com

Carrie Barrack
Senior Advisor, Cato & Clive
Email: carrie@catoandclive.com
Mobile: +61 422 464 028

Media:

Carrie Barrack
Senior Advisor, Cato & Clive
Email: carrie@catoandclive.com
Mobile: +61 422 464 028



About Imricor

Imricor Medical Systems, Inc. (ASX:IMR) is a leading developer of innovative MRI-compatible medical devices which can be used to carry out MRI-guided cardiac catheter ablation procedures. Headquartered in the US, Imricor seeks to make a meaningful impact on patients, healthcare professionals, and healthcare facilities around the world by increasing the success rates and bringing down the overall costs of cardiac catheter ablation procedures.

Imricor's Products

Imricor is a pioneer and leader in developing MRI-compatible products for cardiac catheter ablation procedures, and believes it is the first company in the world to bring commercially viable and safe MRI-compatible products to the cardiac catheter ablation market.

The Vision-MR Ablation Catheter is the Company's prime product offering, specifically designed to work under real-time MRI guidance, with the intent of enabling higher success rates along with a faster and safer treatment compared to conventional procedures using x-ray guided catheters. The Vision-MR Ablation Catheter has been approved in the European Union with an indication for treating type 1 atrial flutter. Imricor intends to seek approval for expanded indications in the future. The Company is also in the early stages of pursuing the required regulatory approvals to place its key products on the market in Australia and the U.S.

The Company has also obtained approval within the EU for the sale of the Advantage-MR EP Recorder/Stimulator System and its consumable product, the Vision-MR Dispersive Electrode.

Imricor expects to sell its capital and consumable products to hospitals and clinics for use in Interventional Cardiac Magnetic Resonance Imaging (iCMR) labs, in which ablation procedures using the Vision-MR Ablation Catheter can be performed. An iCMR lab is an interventional lab that is fitted with MRI equipment for use in cardiac diagnostic and interventional procedures. The installation of iCMR labs is driven primarily by MRI equipment vendors working collaboratively with Imricor. Vendors such as Koninklijke Philips N.V. and Siemens Healthcare GmbH help to target certain sites and support the design and construction of iCMR labs for those sites.

Foreign Ownership Restrictions

Imricor's CHESS Depositary Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933, including the rules and regulations promulgated thereunder (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on the Company's management's beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, EU commercial market acceptance and EU sales of our product as well as our expectations with respect to our ability to develop and commercialise new products. Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Imricor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Imricor may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.